Abstract:Chemotherapy induces ovarian failure in female children and young female cancer survivors. It has been shown that doxorubicin (DOX), an antitumor drug of the anthracycline group, causes gonadotoxicity via the stimulation of oxidative stress. The inhibition of glycogen synthase kinase-3 (GSK-3) was reported to be able to regulate oxidative stress. The present study assessed whether GSK-3 inhibition confers protection to the ovary against DOX-induced oxidative stress damage. An intraperitoneal injection of DOX was used to induce oxidative damage in the mouse ovary, while the inhibition of GSK-3 was achieved by the administration of SB216763, a small and potent GSK-3 inhibitor. DOX increased the mRNA expression levels of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and the antioxidant genes heme-oxygenase-1 (HO-1) and catalase (CAT), while reducing the levels of glutathione peroxidase (GSH-Px) and superoxide dismutase-1 (SOD-1) compared with those of the control. When the GSK-3 inhibitor was combined with DOX increased more expression levels of Nrf2 mRNA and restored levels of GSH-Px and SOD-1 mRNA similar to those in the control group. DOX remarkably decreased the Nrf2 protein expression compared to that in the control, which was significantly associated with increased MDA levels. Interestingly, the SB216763 and DOX coadministration restored the Nrf2 protein expression and MDA levels to levels that were similar to those in the control. DOX significantly decreased the number of primordial, primary, preantral and antral follicles while increasing the number of atretic follicles compared to those in the control. SB216763 caused the drastic recovery of these follicles from the DOX effects. SB216763 and DOX coadministration significantly reduced the apoptotic index compared with that with DOX treatment. DOX decreased the serum AMH and E2 levels and increased the FSH levels compared to those in the controls. However, SB216763 and DOX coadministration restored AMH and E2 while decreasing the FSH levels compared to those in the DOX-treated group. In addition, SB216763 and DOX coadministration reduced the mature oocyte abnormalities that resulted from DOX-induced ovarian damage. Given these results, we suggest that GSK-3/Nrf2 is a promising protective pathway against doxorubicin-induced oxidative damage to the ovaries of females at reproductive ages. Thus, GSK-3 could be an attractive target for the research and development of new drugs for preserving ovarian function during chemotherapy.

Increased cellular senescence in doxorubicin-induced murine ovarian injury: effect of senolytics

Senotherapy Protects against Cisplatin-Induced Ovarian Injury by Removing Senescent Cells and Alleviating DNA Damage

Protective properties of glycogen synthase kinase-3 inhibition against doxorubicin-induced oxidative damage to mouse ovarian reserve.

Doxorubicin Exposure Affects Oocyte Meiotic Maturation Through DNA Damage-Induced Meiotic Arrest

A comprehensive multi-omics signature of doxorubicin-induced cellular senescence in the postmenopausal human ovary.

Senolytic drugs dasatinib and quercetin combined with Carboplatin or Olaparib reduced the peritoneal and adipose tissue metastasis of ovarian cancer

The Role of Cellular Senescence in Cyclophosphamide-Induced Primary Ovarian Insufficiency

Chemotherapy impairs ovarian function through excessive ROS-induced ferroptosis

Characterization of Cellular Senescence in Doxorubicin-Induced Aging Mice.

SIRT1 reduction contributes to doxorubicin–induced oxidative stress and meiotic failure in mouse oocytes

Resveratrol alleviates chemotherapy-induced oogonial stem cell apoptosis and ovarian aging in mice

Depletion of SASP senescent cardiomyocytes with senolytic drugs confers therapeutic effects in doxorubicin‐related cardiotoxicity

Resveratrol attenuates doxorubicin-induced meiotic failure through inhibiting oxidative stress and apoptosis in mouse oocytes.

Ginsenoside Rh2 Ameliorates Doxorubicin-Induced Senescence Bystander Effect in Breast Carcinoma Cell MDA-MB-231 and Normal Epithelial Cell MCF-10A

Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse.

Underlying the Mechanisms of Doxorubicin-Induced Acute Cardiotoxicity: Oxidative Stress and Cell Death

Doxorubicin-Induced Cancer Cell Senescence Shows a Time Delay Effect and is Inhibited by Epithelial-Mesenchymal Transition (EMT)

SS-31 Attenuates Doxorubicin-induced Cardiomyoblast H9C2 Cell Senescence

Resveratrol alleviates doxorubicin-induced damage in mice ovary

Cellular senescence: a double-edged sword in cancer therapy

Resveratrol activation of SIRT1/MFN2 can improve mitochondria function, alleviating doxorubicin‐induced myocardial injury